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Abstract
Purpose REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone
metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy.
Methods Radium-223 was administered in routine clinical practice. Interim safety analysis was planned after enrolment of the
first 600 patients. Patient characteristics and safety data by previous administration of chemotherapy (docetaxel and/or
cabazitaxel) were investigated.
Results This interim analysis included 583 patients. Median duration of observation was 7 months (range, 0–20). Nineteen patients
treated with concomitant chemotherapy were excluded, 564 (97%) were eligible for exploratory analysis according to prior use of
chemotherapy; 190 (34%) had previously received and completed chemotherapy, and 374 (66%) had not. In the prior versus no prior
chemotherapy group, a higher proportion of patients had an Eastern Cooperative Oncology Group performance status of ≥2 (22% vs
11%) and > 20metastatic lesions (26% vs 15%),median alkaline phosphatase (162.0 vs 115.0U/L) and prostate-specific antigen (132.0
vs 40.2 ng/mL) levels were higher, and a lower proportion completed 6 radium-223 injections (45% vs 63%). Drug-related treatment-
emergent adverse events (TEAEs) occurred in 63 and 48%, and haematological drug-related TEAEs in 21 and 9% of patients who had
or had not previously received chemotherapy. Four drug-related deaths were reported, all in the prior chemotherapy group.
Conclusions The short-term safety profile of radium-223 in routine clinical practice was comparable to other clinical studies,
irrespective of prior chemotherapy use. Haematological TEAEs occurred more frequently in the prior chemotherapy group,
presumably due to decreased bone marrow function as a consequence of more advanced disease and prior exposure to cytotoxic
therapy. Patients who had not previously received chemotherapy appeared to have a lower burden of disease at baseline, and a
lower proportion discontinued radium-223 treatment.
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Introduction
Radium 223 dichloride (radium-223), a first-in-class, bone
seeking, targeted alpha therapy, is used in the treatment of
patients with mCRPC and symptomatic bone metastases.
This followed reported prolonged overall survival and a
favourable safety profile in patients treated with best standard
of care (BSoC) and radium-223 compared with BSoC and
placebo in the ALSYMPCA study [1].
Docetaxel with androgen deprivation therapy is used for
the treatment of patients with metastatic hormone-sensitive
prostate cancer [2–4]. Chemotherapy (docetaxel and
cabazitaxel) may also be used for treating patients with
mCRPC [4–6]. Whilst there is a survival benefit for patients
with mCRPC receiving chemotherapy, treatment can be asso-
ciated with toxic effects, including myelosuppression, and
many patients are not healthy enough to receive chemotherapy
or else may decline such treatment [7].
There are currently no level 1 data to guide the optimal
sequencing of chemotherapy and radium-223 in patients with
mCRPC. In the ALSYMPCA study a pre-specified subgroup
analysis showed that radium-223 compared with placebo was
found to be effective and well tolerated irrespective of previ-
ous docetaxel use [7]. Further exploratory analysis from the
phase 3 study suggested that chemotherapy appeared to be
well tolerated when given after radium-223 in patients with
CRPC and symptomatic bone metastases [8]. Therefore, it is
important to assess the safety of radium-223 in the setting of
routine clinical practice, both in patients who have previously
been treated with chemotherapy and in those who have not. In
addition, identifying patient and disease characteristics that
could select those most able to tolerate full scheduled treat-
ment with radium-223 may optimise treatment outcome with
this agent and facilitate effective sequencing with other life-
prolonging therapies.
REASSURE is a prospective, global non-interventional
study that recruited patients with mCRPC who were to be
treated with radium-223 in routine clinical practice. The pri-
mary aim of REASSURE is to investigate long-term safety
(including the incidence of second primary malignancies)
over a 7-year period. The REASSURE study has allowed
the collection of a substantial data set that reflects the current
treatment paradigm for mCRPC and offers important insights
into current routine clinical practice as we seek to maximise
our opportunity to improve patient survival. Here we report an
analysis of patient characteristics and safety data from the first
planned interim analysis of REASSURE in patients grouped
by previous administration of chemotherapy. The incidence of
second primary malignancies will be reported after a longer
duration of follow-up.
Patients and methods
Study design and treatment
The REASSURE study is a prospective, non-interventional
study that planned to enrol patients from at least 150 sites in
North America, Latin America, Europe, and Israel. Eligible
patients had histologically or cytologically confirmed
castration-resistant adenocarcinoma of the prostate with bone
metastases and no known visceral metastases, and had provid-
ed signed informed consent. Patients previously treated with
radium-223, those currently participating in any clinical trial,
or patients for whom systemic treatment with other radiophar-
maceuticals for any indication was planned, were excluded
from the study.
The decision to treat with radium-223, agreed between the
physician and the patient was made within current practice,
independently from, and prior to, the provision of study
information.
Radium-223 treatment was prescribed and administered as
part of usual clinical practice and according to the locally
approved label.
The study is registeredwithClinicalTrials.govNCT02141438.
Assessments
The primary endpoints of the REASSURE study are the inci-
dence of second primary malignancies, the incidence of
treatment-emergent serious adverse events (SAEs), drug-
related treatment-emergent adverse events (TEAEs), drug-
related SAEs (up to 7 years after the last administration),
and bone marrow suppression. Adverse events occurring from
radium-223 initiation through 30 days after the last radium-
223 injection were classified as treatment-emergent. Adverse
events were coded using the Medical Dictionary for
Regulatory Activities (MedDRA), version 19.0, and graded
by the National Cancer Institute-Common Terminology
Criteria for Adverse Events (NCI-CTCAE), version 4.03.
Haematological toxicity was defined by the following adverse
events (MedDRA preferred terms): anaemia (anaemia,
haemoglobin decreased, and red blood cell count decreased);
thrombocytopenia (thrombocytopenia and platelet count de-
creased); leukopenia (leukopenia and white blood cell count
decreased); lymphopenia, (lymphopenia and lymphocyte
count decreased), and neutropenia (neutropenia and neutro-
phil count decreased), pancytopenia, and bonemarrow failure.
Bone marrow suppression was indicated by the use of thera-
peutic or prevention measures (blood transfusion/erythropoi-
etin/colony growth-stimulating factors) up to 6 months after
the last administration of radium-223, and the occurrence of
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all post-treatment grade 3/4 haematological toxicities up to
6 months after last administration of radium-223 as adverse
events or SAEs.
An adverse event was considered to be serious if it: resulted
in death; was life threatening; required hospitalisation (unless
the admission resulted in a hospital stay of ≤12 h, or the ad-
mission was pre-planned); resulted in persistent or significant
disability or incapacity, resulted in a congenital anomaly or
birth defect in an offspring; was medically important. A drug-
related adverse event was considered as any adverse event
judged by the treating physician or radium-223-
administering physician (if applicable) as having a reasonable
suspected causal relationship to radium-223. In this report,
relatedness to study drug (causality assessment) reflected the
opinion provided by the reporting investigator.
Statistics
The REASSURE study aimed to enrol 1200 evaluable pa-
tients overall. The first safety interim analysis was planned
after the first 600 patients had been enrolled. On 15
February 2016, 602 patients had been enrolled and were iden-
tified as patients for the interim analysis. To allow for an
approximate 6 months of follow-up, the data cut-off for the
interim analysis was 22 September 2016, and included 583
patients who provided signed informed consent and who had
received at least one radium-223 injection.
Descriptive analyses were performed on the following sub-
groups of patients: the prior chemotherapy group included
patients who had previously received and completed chemo-
therapy (docetaxel and/or cabazitaxel) which ended before
starting radium-223; the no prior chemotherapy group includ-
ed patients who had not previously received any chemothera-
py (docetaxel and/or cabazitaxel). These patients may have
received chemotherapy during the follow-up period after dis-
continuation of radium-223.
Concomitant treatment was defined as any possible overlap
of the medication(s) during radium-223 administration.
Results
Patients
At the time of this interim analysis, the median duration of
observation of the 583 eligible patients from radium-223 ini-
tiation to end of observation was 7 months (range, 0–
20 months). Nineteen of these 583 (3%) patients had possible
concomitant treatment with chemotherapy and were thus ex-
cluded from the exploratory analysis (Online Resource 1).
Therefore, analysis according chemotherapy subgroups was
performed on 564 patients: 190 (34%) in the prior chemother-
apy group and 374 (66%) in the no prior chemotherapy group.
Baseline and disease characteristics of these patients are
summarised in Table 1. The median age of patients was
73 years (range, 44–94 years), with 78% having an Eastern
Cooperative Oncology Group (ECOG) performance status of
0 or 1. A high proportion of patients who had previously
received chemotherapy were enrolled in Europe and Israel
(74%), and the rest were enrolled in North America (26%).
One hundred and twenty-three of 190 patients (65%) who had
previously received and completed chemotherapy and 107 of
374 patients (29%) who had not, had also received and com-
pleted abiraterone and/or enzalutamide prior to radium-223.
Patients who had been treated with chemotherapy prior to
radium-223 appeared to have poorer baseline characteristics
than those who had not (Table 1). This included a higher
proportion of patients with an ECOG performance status of
2 or 3 (22% vs 11%), a higher proportion with >20 metastatic
lesions (not including superscan), as observed on bone scans
(26% vs 15%), and higher median levels of prostate-specific
antigen (PSA, 132.0 vs 40.2 ng/mL) and alkaline phosphatase
(ALP, 162.0 vs 115.0 U/L), in the group who had previously
received chemotherapy compared with those who had not. In
addition, patients previously treated with chemotherapy had
longer median times with castration-resistant disease (23 vs
10 months) and with bone metastases (34 vs 19 months) be-
fore study entry.
Eighty-five of 190 patients (45%) who had received che-
motherapy prior to radium-223, and 237 of 374 patients (63%)
who had not previously received chemotherapy, had complet-
ed six radium-223 injections; the median number of radium-
223 injections was five and six, respectively, in these groups
(Table 2). Fifty-nine (31%) patients who had previously re-
ceived chemotherapy and 148 (40%) who had not, were treat-
ed with concomitant abiraterone and/or enzalutamide.
Safety
Overall safety data are summarised in Table 3. In total, 300 of
564 patients (53%) experienced any adverse event. Drug-
related TEAEs were reported in 213 patients (38%), the most
common of which were gastrointestinal disorders in 118 pa-
tients (21%) and haematological toxicities in 73 patients
(13%). Drug-related TEAEs were recorded in 78 of 190
(41%) patients who had received prior chemotherapy and
135 of 374 (36%) patients who had not; most of these were
gastrointestinal disorders, which occurred in 41 (22%) and 77
(21%) patients, respectively. Haematological toxicities were
reported in 39 of 190 (21%) patients who had received prior
chemotherapy and 34 of 374 (9%) patients who had not.
Drug-related TEAEs by MedDRA preferred term and
worst NCI-CTCAE grade occurring in ≥3% of patients in
any treatment group or selected for relevance for chemother-
apy are summarized in Table 4. Differences in the observed
frequency of drug-related TEAEs byMedDRA preferred term
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of any grade between patients who had received previous
chemotherapy and those who had not, included anaemia
(15% vs 7%), leukopenia (3% vs 1%), thrombocytopenia
(5% vs 3%), and nausea (13% vs 9%). The most common
grade 3 or 4 drug-related TEAE was anaemia, which was
reported in 23 of 564 patients (4%), occurring in 15 of 190
patients (8%) who had received prior chemotherapy and 8 of
374 (2%) who had not. Grade 3 or 4 fractures in the prior







Age, median [range], years 71 [44–90] 74 (52–94) 73 [44–94]
Region
Europe and Israel 141 (74) 185 (49) 326 (58)
North America 49 (26) 189 (51) 238 (42)
Time between disease stages, median [range], months
Diagnosis to castration resistancea 27 [0–181] 25 (0–236) 25 [0–236]
Castration resistance to study entryb 23 [1–108] 10 (0–147) 14 [0–147]
Bone metastases to study entryc 34 [<1–167] 19 (<1–236) 23 [<1–236]
Metastases other than boned 49 (26) 62 (17) 111 (20)
ECOG performance status
0 39 (21) 119 (32) 158 (28)
1 98 (52) 185 (49) 283 (50)
2 35 (18) 30 (8) 65 (12)
3 6 (3) 13 (3) 19 (3)
missing 12 (6) 27 (7) 39 (7)
Extent of metastatic diseasee
Normal/abnormalf 7 (4) 10 (3) 17 (3)
< 6 18 (10) 77 (22) 95 (18)
6–20 82 (45) 176 (51) 258 (49)
> 20 47 (26) 53 (15) 100 (19)
Superscan 16 (9) 18 (5) 34 (6)
Missing 12 (7) 11 (3) 23 (4)
Laboratory values, median [Q1–Q3]
PSA, ng/mLg 132.0 [38.9–379.2] 40.2 [9.8–153.5] 61.0 [15.4–241.0]
ALP, U/Lh 162.0 [90.0–367.0] 115.0 [73.0–233.0] 132.0 [78–277.0]
LDH, U/Li 279.0 [196.0–405.0] 262.0 [203.0–432.0] 267.4 [200.0–415.0]
Neutrophils ×109/Lj 4.2 [3.3–6.0] 4.2 [3.0–5.7] 4.2 [3.1–5.7]
Platelets × 109/Lk 236 [197.0–301.0] 233 [190.0–280.0] 233 [193.0–289.0]
Haemoglobin, g/dLl 11.8 [10.4–13.0] 12.3 [11.3–13.3] 12.1 [11.0–13.2]
Prior completed use of abiraterone/enzalutamide 123 (65) 107 (29) 230 (41)
Data are n (%) unless otherwise stated
ALP alkaline phosphatase, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PSA prostate-specific antigen
a Total patients n = 234, prior chemotherapy n = 84, no prior chemotherapy n = 150
b Total patients n = 280, prior chemotherapy n = 100, no prior chemotherapy n = 180
c Total patients n = 391, prior chemotherapy n = 138, no prior chemotherapy n = 253
d Including soft tissue progression in bone (epidural), locoregional expansion (rectum/urethra), visceral metastases (lung, kidney, liver, thyroid and
adrenal gland) and distant lymph nodes
e Total patients n = 527, prior chemotherapy n = 182, no prior chemotherapy n = 345. For patients with multiple baseline assessments, the worst value is
considered. The % base is the number of patients for whom bone scan has been documented at respective visit
f Normal or abnormal due to benign bone disease
g Total patients n = 395, prior chemotherapy n = 150, no prior chemotherapy n = 245
h Total patients n = 399, prior chemotherapy n = 145, no prior chemotherapy n = 254
i Total patients n = 200, prior chemotherapy n = 85, no prior chemotherapy n = 115
j Total patients n = 372, prior chemotherapy n = 138, no prior chemotherapy n = 234
k Total patients n = 487, prior chemotherapy n = 169, no prior chemotherapy n = 318
l Total patients n = 497, prior chemotherapy n = 172, no prior chemotherapy n = 325
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chemotherapy group included a femoral neck fracture, a hip
fracture, and a spinal compression fracture, and in the no prior
chemotherapy group included a femur fracture, a hip fracture,
and a humerus fracture (Online Resource 2).
The incidence of treatment discontinuation due to
treatment-emergent drug-related adverse events was low, oc-
curring in 34 of 564 patients (6%) overall, including 17 of 190
(9%) who had previously been treated with chemotherapy,
and 17 of 374 (5%) patients who had not (Table 3).
Drug-related SAEs occurred in 13 of 190 (7%) patients who
had previously received chemotherapy and 12 of 374 (3%)who
had not, the most common of which were haematological tox-
icities reported in eight and five patients, respectively.
Post-treatment grade 3 or 4 bone marrow suppression
events were reported in 50 of 564 patients (9%), occurring
in 24 of 190 (13%) who had received prior chemotherapy
and in 26 of 374 (7%) who had not (Online Resource 3).
The most common were haematopoietic erythropenia in
11% vs 6% and thrombocytopenia in 4% vs 2% of patients
who had or had not previously received chemotherapy.
Blood transfusions were received prior to radium-223 ther-
apy in 46 of 546 patients (8%) and concomitantly with
radium-223 in 68 patients (12%), including 21 (4%) who re-
ceived transfusions both before and during radium-223 thera-
py. Patients who had received prior chemotherapy were more
likely to undergo blood transfusions than those who had not,
either prior to radium-223 (17% vs 5%) or concomitantly with
radium-223 (21% vs 8%) (Table 5).
There were four reported drug-related SAEs leading to
death, all occurring in patients who had received prior chemo-
therapy. These included one patient each with anaemia, pan-
cytopenia, and monocytic leukaemia, and one patient where
the event was not reported.
Discussion
The data from the first interim analysis of the REASSURE
study demonstrated that radium-223 had a good short-term
safety profile in patients with mCRPC with bone metastases







Any AE 119 (63) 181 (48) 300 (53)
Drug-related TEAE 78 (41) 135 (36) 213 (38)
Worst grade ≥ 3 25 (13) 25 (7) 50 (9)
Leading to permanent discontinuation of radium-223 17 (9) 17 (5) 34 (6)
Treatment-emergent SAE 66 (35) 73 (20) 139 (25)
Leading to hospitalization or prolongation of existing hospitalization 55 (29) 63 (17) 118 (21)
Leading to permanent discontinuation of radium-223 31 (16) 37 (10) 68 (12)
Leading to death 24 (13) 12 (3) 36 (6)
Drug-related SAE 13 (7) 12 (3) 25 (4)
Leading to permanent discontinuation of radium-223 4 (2) 5 (1) 9 (2)
Leading to death 4 (2) 0 4 (<1)
AE adverse event, SAE serious adverse event, TEAE treatment-emergent adverse event
Table 2 Summary of radium-223







Median [Q1–Q3] 5 [3–6] 6 [4–6] 6 [3–6]
Number completed
1–3 65 (34) 85 (23) 150 (27)
4 22 (12) 31 (8) 53 (9)
5 18 (9) 21 (6) 39 (7)
6 85 (45) 237 (63) 322 (57)
Duration of treatment,
median [range], months
3.7 [<0.1–7.2] 4.6 [<0.1–6.7] 4.6 [<0.1–7.2]
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treated in routine clinical practice across the European Union,
Israel, and the United States. These findings are in line with the
safety profiles previously reported for radium-223 in patients
with bone mCRPC in the clinical trial setting [1, 9, 10].
Compared with the ALSYMPCA study [1], patients in the
present analysis tended to have less advanced disease, as evi-
denced by fewer metastatic lesions (≤20 lesions in 67% vs 59%
and superscan in 6% vs 9%) and lower median levels of PSA
(61 ng/mL vs 146 ng/mL) and ALP (132 U/L vs 211 U/L).
For many years, docetaxel was the only systemic treatment
option with a proven survival benefit for mCRPC [5, 6].
However, more recently, abiraterone, enzalutamide,
sipuleucel-T (only in the United States), cabazitaxel, and
radium-223 are survival-prolonging treatment options for
patients with mCRPC [4, 11]. The optimal patient profile for
radium-223, and its best use in sequence with the other ap-
proved agents, however, is unclear, with no level 1 evidence
reported and few consensus opinions available. In the present
analysis, patients who had not previously received chemother-
apy appeared to have less advanced disease than patients who
had received prior chemotherapy, as suggested by their more
favourable baseline disease characteristics, including a shorter
time for which tumours had been castration-resistant, fewer
patients with an ECOG performance status ≥2, the presence of
fewer metastatic lesions, and lower baseline PSA and ALP
levels. In addition, patients who had not previously received
chemotherapy more often completed six radium-223 injec-
tions than those who had received prior chemotherapy.
Table 4 Drug-related treatment-
emergent adverse events by




















At least one TEAE 78 (41)a 22 (12) 135 (36)b 25 (6) 213 (38)c 47 (8)
Haematological
At least one eventd 39 (21) 16 (8) 34 (9) 16 (4) 73 (13) 32 (6)
Anaemiae 28 (15) 15 (8) 27 (7) 8 (2) 55 (10) 23 (4)
Thrombocytopeniaf 9 (5) 3 (2) 10 (3) 3 (1) 19 (3) 6 (1)
Leukopeniag 5 (3) 0 3 (1) 1 (<1) 8 (1) 1 (<1)
Lymphopeniah 1 (<1) 0 4 (<1) 1 (<1) 5 (<1) 1 (<1)
Neutropeniai 3 (2) 0 3 (<1) 2 (<1) 6 (1) 2 (<1)
Pancytopenia 3 (2) 0 3 (1) 2 (<1) 6 (1) 2 (<1)
Bone marrow
failure
2 (1) 0 1 (<1) 1 (<1) 3 (<1) 1 (<1)
Non haematological
Diarrhoea 19 (10) 0 46 (12) 2 (<1) 65 (12) 2 (<1)
Nausea 24 (13) 0 33 (9) 0 57 (10) 0
Vomiting 8 (4) 0 14 (4) 0 22 (4) 0
Fatigue 14 (7) 2 (1) 29 (8) 1 (<1) 43 (8) 3 (<1)
Data are number of patients (%) reported by MedDRA preferred terms and NCI-CTCAE worst grade in ≥3% of
patients in any treatment group or selected for relevance to chemotherapy and radium-223. Drug-related TEAEs:
up to 30 days after last radium-223 administration
MedDRAMedical Dictionary for Regulatory Activities version 19. TEAE treatment-emergent adverse event
a Includes six patients where data are missing
b Includes two patients where data are missing
c Includes eight patients where data are missing
d Includes anaemiae , thrombocytopeniaf , leukopeniag , lymphopeniah , neutropeniai , pancytopenia, and bone
marrow failure
e Anaemia is defined by MedDRA preferred terms: Anaemia, Haemoglobin decreased, and Red blood cell count
decreased
f Thrombocytopenia is defined by MedDRA preferred terms: Thrombocytopenia and Platelet count decreased
g Leukopenia is defined by MedDRA preferred terms: Leukopenia and White blood cell count decreased
h Lymphopenia is defined by MedDRA preferred term: Lymphopenia and Lymphocyte count decreased
i Neutropenia is defined by MedDRA preferred terms: Neutropenia and Neutrophil count decreased
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Similarly, completion of radium-223 was reported to be more
likely in patients with less advanced disease (as defined by
better baseline characteristics) treated in a community-based
setting [12, 13]. Furthermore, the better safety profile and
lower rates of treatment discontinuation reported in patients
who had not previously received chemotherapy compared
with those who had, might also suggest that patients with
mCRPC and bone metastases may benefit from radium-223
earlier in their treatment course, before administration of che-
motherapy. Alternatively, this may simply reflect incomplete
recovery from the prior effects of chemotherapy in the previ-
ously treated patient group.
Bone marrow function is often compromised in patients
with bone metastases [14]; therefore, assessing bone marrow
suppression and the need for bone-targeting treatments is of
interest in this patient group. In contrast to radiopharmaceuti-
cals that emit long-range beta particles, the short-range alpha
particles emitted by radium-223 theoretically result in a more
localised effect, with less bone marrow suppression and fewer
related adverse events [15, 16]. In the current post hoc analy-
sis, blood transfusions were received by 46 patients (8%) prior
to initiation of radium-223 and by 68 patients (12%) during
the course of radium-223 therapy; 21 of these patients re-
ceived transfusions both before and during radium-223 thera-
py. Notably, patients who had received prior chemotherapy
were more likely to have received blood transfusions prior to
receiving radium-223, or concomitantly with radium-223. In
the ALSYMPCA study, 42% of patients required blood trans-
fusions from randomisation to study end. Post hoc analyses
from the ALSYMPCA study identified significant baseline
predictors for haematological toxicity related to radium-223
treatment, which included the extent of bone disease, PSA
levels, decreased haemoglobin levels and platelet counts,
and prior chemotherapy use [17]. The authors recommended
that such factors should be considered in the management of
patients with mCRPC treated with radium-223.
In this analysis, drug-related haematological SAEs oc-
curred more frequently in patients with a history of prior che-
motherapy use; these patients generally had a higher burden of
bone disease and more often discontinued treatment, suggest-
ing that the higher haematological adverse event rate was per-
haps a consequence of prior treatment and/or disease stage
rather than radium-223-related toxicity. Subsequent analyses
of the REASSURE study may help clarify the long-term ef-
fects of radium-223 on bone marrow. Safety studies such as
this play a critical role in helping to determine the optimal
treatment approach for patients.
This study provides the opportunity to prospectively collect
safety data on radium-223 in routine clinical practice, although
caution must be used in interpreting the results due to the ob-
servational nature of the study. In particular, the single-arm
study design does not allow comparison with a control group.
The current analysis is of particular interest, since radium-223 is
commonly administered later in the disease course, often after
chemotherapy and in patients that are considered not suitable
for chemotherapy or where chemotherapy is contraindicated [1,
18, 19]. Some physicians consider that it is important for man-
agement of the disease that the opportunity is provided to ad-
minister as many of the available life-prolonging therapies as
possible. Therefore, it may be the case that radium-223 might
be better placed early in the disease course during initial lines of
treatment, but must be placed prior to the onset of visceral
disease (lung, liver, or other organ metastases) [20].
Although the short follow-up time for this interim analysis
precluded data on overall survival, subgroup analyses from
the ALSYMPCA trial showed an overall survival benefit for
radium-223 irrespective of prior docetaxel use [7].
Exploratory analyses suggested that administration of doce-
taxel following radium-223 was viable, well tolerated, and did
not adversely affect overall survival [8]. Long-term safety and
outcomes on all patients in REASSURE will be reported in
the next interim analysis, expected in 2019.
In conclusion, the short-term safety profile of radium-223,
when used in routine clinical practice settings in patients with
mCRPC with bone metastases, was comparable to other clin-
ical studies, regardless of prior chemotherapy use, with no
unexpected findings reported. Drug-related SAEs were most
often haematological and occurred more frequently in patients
with a history of prior chemotherapy use and a higher burden
of disease, which could potentially be due to advanced disease
or toxicity from prior chemotherapy. Patients who had not
previously received chemotherapy appeared to have a lower
burden of disease at baseline, experienced a lower incidence
of haematological adverse events, and discontinued radium-







Prior to radium-223 32 (17) 14 (5) 46 (8)
Concomitant with radium-223 39 (21) 29 (8) 68 (12)
Both prior to and concomitant with radium-223 17 (9) 4 (1) 21 (4)
Data presented are n (%)
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223 treatment less often. These results may suggest that se-
lected patients with mCRPC with bone metastases may bene-
fit from the use of radium-223 earlier in the course of treat-
ment, before treatment with chemotherapy.
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